{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:02:37Z","timestamp":1787025757727,"version":"build-2736575974"},"reference-count":69,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Clovis"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genmab"},{"name":"Tesaro"},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Easai"},{"DOI":"10.13039\/100004917","name":"CPRIT","doi-asserted-by":"publisher","award":["RP120214"],"award-info":[{"award-number":["RP120214"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Ann Rife Cox Chair in Gynecology"},{"name":"Judy Reis"},{"name":"Albert Pisani"},{"name":"MD Anderson ovarian cancer research fund"},{"name":"American Association of Obstetricians and Gynecologists Foundation"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["5T32CA101642"],"award-info":[{"award-number":["5T32CA101642"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.hoc.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T12:21:02Z","timestamp":1541074862000},"page":"965-982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Management and Treatment of Recurrent Epithelial Ovarian Cancer"],"prefix":"10.1016","volume":"32","author":[{"given":"Shannon","family":"Armbruster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Alejandro","family":"Rauh-Hain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2018.07.005_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2004.07.008","article-title":"Timing isn\u2019t everything: an analysis of when to start salvage chemotherapy in ovarian cancer","volume":"95","author":"McMeekin","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.hoc.2018.07.005_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2005.03.003","article-title":"Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature","volume":"55","author":"Gadducci","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.005_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2018.07.005_bib4","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"9375","key":"10.1016\/j.hoc.2018.07.005_bib5","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.hoc.2018.07.005_bib6","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2018.07.005_bib7","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2018.07.005_bib8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.hoc.2018.07.005_bib9","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.005_bib10","first-page":"33","article-title":"Tumor angiogenesis in advanced stage ovarian carcinoma","volume":"147","author":"Hollingsworth","year":"1995","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.005_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6","article-title":"Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas","volume":"69","author":"Gasparini","year":"1996","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.005_bib12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00004347-199707000-00011","article-title":"The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer","volume":"16","author":"Nakanishi","year":"1997","journal-title":"Int J Gynecol Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2018.07.005_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jnci\/90.6.447","article-title":"Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice","volume":"90","author":"Yoneda","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.005_bib14","first-page":"587","article-title":"The prognostic significance of angiogenesis in epithelial ovarian carcinoma","volume":"5","author":"Alvarez","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"33","key":"10.1016\/j.hoc.2018.07.005_bib15","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1200\/JCO.2007.13.6150","article-title":"Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?","volume":"25","author":"Kaye","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.005_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A\u00a0phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"33","key":"10.1016\/j.hoc.2018.07.005_bib17","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.hoc.2018.07.005_bib18","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.005_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2016.07.112","article-title":"Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2","volume":"143","author":"Monk","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2018.07.005_bib20","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.005_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2018.07.005_bib22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10023","key":"10.1016\/j.hoc.2018.07.005_bib23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.hoc.2018.07.005_bib24","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1200\/JCO.2017.35.15_suppl.5506","article-title":"Overall survival results of ICON6: a trial of chemotherapy and cediranib in relapsed ovarian cancer","volume":"35","author":"Ledermann","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.005_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2006.11.017","article-title":"Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer","volume":"105","author":"Safra","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2018.07.005_bib26","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2018.07.005_bib27","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2018.07.005_bib28","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1200\/JCO.2008.19.2963","article-title":"Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the gynecologic oncology group","volume":"27","author":"Miller","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2018.07.005_bib29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic oncology group study","volume":"16","author":"Rose","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2018.07.005_bib30","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.005_bib31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80\u00a0mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2018.07.005_bib32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2005.12.017","article-title":"Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study","volume":"102","author":"Petru","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2018.07.005_bib33","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2018.07.005_bib34","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/annonc\/mdw094","article-title":"PARP inhibitors in ovarian cancer","volume":"27","author":"Ledermann","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2018.07.005_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.005_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrc3891","article-title":"Therapeutic opportunities within the DNA damage response","volume":"15","author":"Pearl","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2018.07.005_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.coph.2008.06.016","article-title":"Targeted therapy for cancer using PARP inhibitors","volume":"8","author":"Lord","year":"2008","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"10.1016\/j.hoc.2018.07.005_bib38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"issue":"7353","key":"10.1016\/j.hoc.2018.07.005_bib39","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer","year":"2011","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.hoc.2018.07.005_bib40","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.ejca.2013.05.020","article-title":"A\u00a0phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer","volume":"49","author":"Liu","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2018.07.005_bib41","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2018.07.005_bib42","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2018.07.005_bib43","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.005_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T\u00a0cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2018.07.005_bib45","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.hoc.2018.07.005_bib46","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2018.07.005_bib47","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/jco.2015.33.15_suppl.5510","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study","volume":"33","author":"Varga","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.005_bib48","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.hoc.2018.07.005_bib49","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2018.07.005_bib50","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2018.07.005_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1758834016687254","article-title":"PARP inhibitors in ovarian cancer: evidence, experience and clinical potential","volume":"9","author":"Evans","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.005_bib52","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.005_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10106","key":"10.1016\/j.hoc.2018.07.005_bib54","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2018.07.005_bib55","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1200\/JCO.2016.34.15_suppl.5533","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity","volume":"34","author":"Disis","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.005_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1016\/j.hoc.2018.07.005_bib57","doi-asserted-by":"crossref","unstructured":"Konstantinopoulos PA, Munster P, Forero-Torez A, et\u00a0al. Topacio: preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1\/2 study of niraparib in combination with pembrolizumab. In: 49th Annual Meeting of the Society of Gynecologic Oncology. New Orleans, LA, March 24\u201327, 2018.","DOI":"10.1016\/j.ygyno.2018.04.554"},{"key":"10.1016\/j.hoc.2018.07.005_bib58","doi-asserted-by":"crossref","unstructured":"Drew Y, de Jonge M, Hong SH, et\u00a0al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC). In: 49th Annual Meeting of the Society of Gynecologic Oncology. New Orleans, LA, March 24\u201327, 2018.","DOI":"10.1016\/j.ygyno.2018.04.555"},{"issue":"suppl; abstr 5511","key":"10.1016\/j.hoc.2018.07.005_bib59","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study","volume":"36","author":"Matulonis","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2018.07.005_bib60","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2016.34.15_suppl.3015","article-title":"Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women\u2019s cancers (NCT02484404)","volume":"34","author":"Lee","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2018.07.005_bib61","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/bjc.2011.328","article-title":"Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort","volume":"105","author":"Zang","year":"2011","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2018.07.005_bib62","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hoc.2018.07.005_bib63","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2018.07.005_bib64","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11912-012-0260-x","article-title":"Surgery for relapsed ovarian cancer: when should it be offered?","volume":"14","author":"Harter","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.005_bib65","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2014.01.027","article-title":"Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer","volume":"132","author":"Harter","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2018.07.005_bib66","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A\u00a0risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2018.07.005_bib67","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Du Bois","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl; abstr 5501","key":"10.1016\/j.hoc.2018.07.005_bib68","article-title":"A\u00a0phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG Oncology\/Gynecologic","volume":"36","author":"Coleman","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2018.07.005_bib69","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881830755X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881830755X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:11:26Z","timestamp":1760184686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985881830755X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S088985881830755X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2018.07.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management and Treatment of Recurrent Epithelial Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}